STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLGO
  4. [Form 4] BIOLARGO, INC. Insider Trading Activity

BioLargo (BLGO) director granted options in lieu of $18,750 cash fees

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BioLargo director Christina Elaine Bray received a grant of options to purchase 165,198 shares of common stock. The options have an exercise price of $0.1135 per share and were granted as compensation for $18,750 in board fees for the most recently completed quarter under the 2024 Equity Incentive Plan.

Following this grant, she holds options covering a total of 1,546,700 shares. This is a compensation-related award rather than an open-market transaction.

Positive

  • None.

Negative

  • None.
Insider Bray Christina Elaine
Role null
Type Security Shares Price Value
Grant/Award Option to Purchase Common Stock 165,198 $0.00 --
Holdings After Transaction: Option to Purchase Common Stock — 1,546,700 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 165,198 shares Options to purchase common stock granted June 30, 2026
Exercise price $0.1135 per share Strike price for the new stock options
Board fees paid in options $18,750 Quarterly director fees satisfied via option grant
Total options after grant 1,546,700 shares Total option holdings following this transaction
Option expiration June 30, 2036 Expiration date of the granted options
Option to Purchase Common Stock financial
"security_title: "Option to Purchase Common Stock""
2024 Equity Incentive Plan financial
"pursuant to the Issuer's 2024 Equity Incentive Plan"
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
derivative security financial
"transaction_type: "derivative" for the option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bray Christina Elaine
(Last)(First)(Middle)
14921 CHESTNUT ST.
(Street)
WESTMINSTER CALIFORNIA 92683
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock$0.113506/30/2026A165,19806/30/202606/30/2036Common Stock165,198(1)1,546,700D
Explanation of Responses:
1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.
/s/ John R. Browning, attorney-in-fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did BioLargo (BLGO) director Christina Elaine Bray report on this Form 4?

Christina Elaine Bray reported receiving an option grant for 165,198 shares of BioLargo common stock. The grant is a compensation award for her board service, not an open-market stock purchase or sale, and is documented as a derivative security transaction.

How many BioLargo (BLGO) shares are covered by Christina Bray’s new stock option grant?

The new grant covers options to purchase 165,198 shares of BioLargo common stock. These options represent additional potential future ownership if exercised and are part of her overall equity compensation as a member of the company’s board of directors.

What is the exercise price and term of Christina Bray’s BioLargo (BLGO) stock options?

The options have an exercise price of $0.1135 per share and expire on June 30, 2036. This means she may choose to buy BioLargo shares at $0.1135 any time before that expiration date, subject to the plan’s terms and vesting conditions.

Why did BioLargo (BLGO) grant these options to director Christina Bray?

The options were issued as payment for $18,750 in fees owed for her board service in the most recently completed quarter. Under BioLargo’s 2024 Equity Incentive Plan, directors can receive equity awards instead of cash, aligning compensation with shareholder interests.

What are Christina Bray’s total BioLargo (BLGO) option holdings after this grant?

After this grant, Christina Bray holds options covering 1,546,700 shares of BioLargo common stock. This figure reflects her derivative equity position as reported in the filing and shows her ongoing incentive tied to the company’s long-term performance.